CoChat
Sign Up
Cited by 162Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease

Open access
Sutphen, Courtney L., McCue, Lena, Herries, Elizabeth M., Xiong, Chengjie, Ladenson, Jack H., Holtzman, David M., Fagan, Anne M., On behalf of ADNI·2018·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2018.01.012PMC PMC6110083
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within-person biomarker(s) change over time is critical for trial enrollment and design. METHODS: Longitudinal cerebrospinal fluid samples from the Alzheimer's Disease Neuroimaging Initiative were assayed for novel markers of neuronal/synaptic injury (visinin-like protein 1, Ng, and SNAP-25) and neuroinflammation (YKL-40) and compared with β amyloid 42, tau, and phospho-tau181. General linear mixed models were used to compare within-person rates of change in three clinical groups (cognitively normal, mild cognitive impairment, and Alzheimer's disease) further defined by β amyloid status. RESULTS: Levels of injury markers were highly positively correlated. Despite elevated baseline levels as a function of clinical status and amyloid-positivity, within-person decreases in these measures were observed in the early symptomatic, amyloid-positive Alzheimer's disease group. DISCUSSION: Knowledge of within-person biomarker change will impact interpretation of biomarker outcomes in clinical trials that are dependent on disease stage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.01.012

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Baseline concentrations and estimated within-person 5-year change in CSF biomarkers. Baseline biomarker concentrations (top, gray panel) and estimated group slopes (bottom, white panel) for Aβ42 (A), tTau (B), pTau (C), VILIP-1 (D), SNAP-25 (E), Ng (F), and YKL-40 (G). Baseline is shown for each individual, estimated group slopes of average annual change in five bins defined by diagnostic group and amyloid status are extrapolated to show 5 years of change. A Different from CN− group, B Different from CN + group, C Different from MCI + group, D Different from AD + group, E Different from MCI− group, * Different from 0. Abbreviations: Aβ; β amyloid; tTau, total tau; pTau, phospho-tau; VILIP-1, visinin-like protein 1; SNAP-25, synaptosomal-associated protein 25; Ng, neurogranin; YKL-40, chitinase-3 like-1.
Fig. 1. Baseline concentrations and estimated within-person 5-year change in CSF biomarkers. Baseline biomarker concentrations (top, gray panel) and estimated group slopes (bottom, white panel) for Aβ42 (A), tTau (B), pTau (C), VILIP-1 (D), SNAP-25 (E), Ng (F), and YKL-40 (G). Baseline is shown for each individual, estimated group slopes of average annual change in five bins defined by diagnostic group and amyloid status are extrapolated to show 5 years of change. A Different from CN− group, B Different from CN + group, C Different from MCI + group, D Different from AD + group, E Different from MCI− group, * Different from 0. Abbreviations: Aβ; β amyloid; tTau, total tau; pTau, phospho-tau; VILIP-1, visinin-like protein 1; SNAP-25, synaptosomal-associated protein 25; Ng, neurogranin; YKL-40, chitinase-3 like-1.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I.
Affiliations
  • Washington University in St. Louis (US)
  • Alzheimer’s Disease Neuroimaging Initiative (US)
Corresponding author
Fagan, Anne M.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2018-03-24
Volume
14
Issue
7
Pages
869-879
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2018.01.012
PMC
PMC6110083
OpenAlex
W2791314414
Cited by
162
References
42
Citations by year
2026: 9 · 2025: 13 · 2024: 19 · 2023: 10 · 2022: 22 · 2021: 32 · 2020: 35 · 2019: 18 · 2018: 3
FWCI
17.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health (P50AG005681, P01AG003991, P01AG026276, U01 AG024904)
  • U.S. Department of Defense (W81XWH‐12‐2‐0012)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • Northern California Institute for Research and Education
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, cerebrospinal fluid biomarkers
MeSH terms
Aged, Alzheimer Disease, Cognition, Female, Humans, Longitudinal Studies, Male, Biomarkers, Amyloid beta-Peptides, tau Proteins, Age of Onset, Synaptosomal-Associated Protein 25, Neurocalcin, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review